-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
Kempen 12th edition Life Sciences Conference
15/04/2019
Kempen is proud to host the annual Kempen Life Sciences Conference. On this occasion, Bart Delbaere, Securities Specialist Sales, sounds the gong.
Kempen Life Sciences Conference
The Kempen Life Sciences Conference has become a central meeting place for global institutional investors and European Life Sciences companies. Like previous years, the conference will be attended by executives from a wide range of companies from all around Europe including pharma, biotech, diagnostics, and MedTech.
As one of the few focused merchant banks in Europe, Kempen is positioned as a specialist in the Life Sciences and Healthcare markets. Kempen provides European companies access to a global network of specialist and generalist investors. Last Summer, Kempen was granted approval by the US regulator FINRA to offer our services as an underwriter in ECM transactions in the US.
The team has successfully executed over 100 life sciences transactions since its inception in 2005.
For more information: kempen.com